← All trials
NCT01392209
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 8, 2011
- Primary completion
- Nov 15, 2019
- Completion date
- Nov 15, 2019
- First posted
- Jul 12, 2011
- Last posted
- Nov 22, 2019
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- Columbia UniversityCollaborator
- GenentechCollaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- University of California, San FranciscoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.